



January 2015

Proton Pump Inhibitors in Primary Care

Reference List


1. Source: Medical Beneficiary & Pharmaceutical Services Division, British Columbia Ministry of Health
2. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and *Clostridium difficile* infection: a contemporary systematic review and meta-analysis. *PLoS One*. 2012 Dec;7(12):e50836
3. Deshpande A, Pant C, Pasupuleti V, Rolston DDK, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and *Clostridium difficile* infection in a meta-analysis. *Clin Gastroenterol Hepatol*. 2012 Mar;10(3):225–33
4. Janarthanan S, Ditch I, Adler DG, Ehrnpreis MN. *Clostridium difficile*-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *Am J Gastroenterol*. 2012 Jul;107(7):1001–10
5. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of *Clostridium difficile* infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol*. 2012 Jul;107(7):1011–9
6. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. *Am J Gastroenterol*. 2011 Jul;106(7):1209–18
7. Eom CS, Jeon CY, Lim J-W, Cho E-G, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. *Can Med Assoc J*. 2011 Feb 22;183(3):310–9
8. Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. *J Gastroenterol Hepatol*. 2013 Feb;28(2):235–42
9. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA*. 2013 Dec 11;310(22):2435–42
10. Canadian Agency for Drugs and Technologies in Health. Optimal Therapy Report. Evidence for PPI Use in Gastroesophageal Reflux Disease, Dyspepsia and Peptic Ulcer Disease: Scientific Report. Volume 1, Issue 2. [Internet]. 2007 Mar [cited 2014 Oct 23]. Available from: http://www.cadth.ca/media/compus/reports/compus_Scientific_Report_final.pdf
11. McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors. Final Report Update 5. Portland (OR): Oregon Health & Science University. [Internet]. 2009 May [cited 2014 Oct 23]. Available from: http://derp.ohsu.edu/final/PPI_%20final%20report_update%205_version%204_unshaded_09_May.pdf
12. Ip S, Chung M, Moorthy D, Yu WW, Lee J, Chan JA, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease: Update. Comparative Effectiveness Review No. 29. AHRQ Publication No. 11-EHC049-EF. Rockville, MD: Agency for Healthcare Research and Quality. [Internet]. 2011 Sept [cited 2014 Oct 23]. Available from: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf

BC's Provincial Academic Detailing (PAD) service is offered free of charge to health care professionals. The service is provided by health authorities and supported by the Ministry of Health. Relevant topics are identified in consultation with various groups. All written materials are externally reviewed by clinicians and experts in critical appraisal.

13. U.S. Food and Drug Administration. Nexium (Esomeprazole Magnesium) Delayed-Release Capsules Drug Approval Package. NDA 021153/021154. [Internet]. 2001 [cited 2014 Oct 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21154_Nexium.cfm
14. U.S. Food and Drug Administration. Kapidex (Dexlansoprazole) Delayed-Release Capsules Drug Approval Package. NDA 022287. [Internet]. 2009 [cited 2014 Oct 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000TOC.cfm
15. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. *Cochrane Database Syst Rev.* 2007;(2):CD003244
16. Donnellan C, Preston C, Moayyedi P, Sharma N. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. *Cochrane Database Syst Rev.* 2010;(2):CD003245
17. British Columbia Ministry of Health. Guidelines and Protocols Advisory Committee. Gastroesophageal Reflux Disease - Clinical Approach in Adults. [Internet]. 2010 Jan 30 [cited 2014 Oct 24]. Available from: http://www.bcguidelines.ca/guideline_gerd.html
18. British Columbia Ministry of Health. Guidelines and Protocols Advisory Committee. Dyspepsia with or without *Helicobacter pylori* infection - Clinical Approach in Adults. [Internet]. 2010 Mar 5 [cited 2014 Oct 24]. Available from: http://www.bcguidelines.ca/guideline_dyspepsia.html
19. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2013 Mar;108(3):308–28
20. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. *Can J Gastroenterol.* 2005 Jan;19(1):15–35
21. Canadian Pharmacists Association. Pariet® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
22. Canadian Pharmacists Association. Pantoloc® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
23. Canadian Pharmacists Association. Tecta® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
24. Canadian Pharmacists Association. Losec® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
25. Canadian Pharmacists Association. Prevacid® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
26. Canadian Pharmacists Association. Nexium® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
27. Canadian Pharmacists Association. Dexilant® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>
28. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev.* 2013;(5):CD002095
29. Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. *Cochrane Database Syst Rev.* 2010;(1):CD004060
30. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. *Cochrane Database Syst Rev.* 2011;(1):CD004823
31. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. *Cochrane Database Syst Rev.* 2003;(2):CD001496
32. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. *Cochrane Database Syst Rev.* 2006;(4):CD001960
33. Fass R. Healing erosive esophagitis with a proton pump inhibitor: the more the merrier? *Am J Gastroenterol.* 2012 Apr;107(4):531–3

34. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology*. 2008 Oct;135(4):1383–91.e1–5
35. Dutta U, Yuan Y, Moayyedi P, Leontiadis GI. High dose versus standard dose proton pump inhibitor for short term management of erosive reflux oesophagitis. *Cochrane Database Syst Rev*. Intervention Protocol:CD010581. [Internet]. 2013 Jun 14 [cited 2014 Oct 24] <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010581/abstract>
36. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients. *Cochrane Database Syst Rev*. 2006;(2):CD003840
37. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of *Helicobacter pylori* infection--the Maastricht IV/ Florence Consensus Report. *Gut*. 2012 May;61(5):646–64
38. Van Zanten SV, van der Knoop B. Gastric ulcer treatment: cure of *Helicobacter pylori* infection without subsequent acid-suppressive therapy: is it effective? *Eur J Gastroenterol Hepatol*. 2008 Jun;20(6):489–91
39. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? *Aliment Pharmacol Ther*. 2005 Apr 1;21(7):795–804
40. Blondel-Hill E, Fryters S. Bugs & Drugs, Alberta Health Services, Edmonton. Available from: <http://www.bugsanddrugs.ca/>
41. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev*. 2002;(4):CD002296
42. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Gastrointestinal Drugs Advisory Committee. [Internet]. 2010 Nov 4. [cited 2014 Oct 24]. Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM237496.pdf>
43. Graham DY. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. *Clin Gastroenterol Hepatol*. 2009 Nov;7(11):1147–50
44. Moore AR. Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage. *Arthritis Res Ther*. 2013;15(Suppl 3):S4
45. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. [Internet]. [cited 2014 Oct 24]. Available from: <http://www.cochrane.org/handbook>
46. Nexium® (esomeprazole magnesium) Delayed Release-Capsules Prescribing Information. [Internet]. 2014 [cited 2014 Oct 24]. Available from: <http://www1.astrazeneca-us.com/pi/Nexium.pdf>
47. Health Canada. Drugs and Health Products. Drug Product Database Online Query. [Internet]. Accessed 2014 Dec 1. Available from: <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
48. British Columbia Ministry of Health. BC PharmaCare Formulary Search. [Internet]. Accessed 2014 Nov 1. Available from: <https://pcbl.hlth.gov.bc.ca/pharmacare/benefitslookup/>
49. Lexicomp® Online™. [Internet]. Accessed October 24, 2014. Available from: <http://online.lexi.com/lco/action/interact>
50. Focks JJ, Brouwer MA, van Oijen MGH, Lanas A, Bhatt DL, Verheugt FWA. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome - a systematic review. *Heart Br Card Soc*. 2013 Apr;99(8):520–7
51. Douglas IJ, Evans SJW, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. *BMJ*. 2012;345:e4388
52. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. *Drug Saf Int J Med Toxicol Drug Exp*. 2012 Feb 1;35(2):127–39
53. Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. *Int J Cardiol*. 2013 Aug 10;167(3):965–74
54. Kwok CS, Loke YK. Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors. *Expert Opin Drug Saf*. 2012 Mar;11(2):275–84
55. Canadian Pharmacists Association. Plavix® [product monograph]. e-CPS. [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2014 [cited 2014 Oct 24]. Available from: <https://www.e-therapeutics.ca/>

56. Health Canada. Plavix (blood thinner): New recommendations for use with proton pump inhibitors (antacids). [Internet]. 2011 Sept 22 [cited 2014 Oct 24]. Available from: <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13545a-eng.php>
57. U.S. Food and Drug Administration. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). [Internet]. 2009 Nov 17 [cited 2014 Oct 24]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm190787.htm>
58. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol*. 2007 Sep;102(9):2047–56
59. Reimer C. Safety of long-term PPI therapy. *Best Pract Res Clin Gastroenterol*. 2013 Jun;27(3):443–54
60. Health Canada. Proton pump inhibitors (antacids): possible risk of *Clostridium difficile*-associated diarrhea. [Internet]. 2012 Feb 16 [cited 2014 Oct 24]. Available from: <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13651a-eng.php>
61. U.S. Food and Drug Administration. FDA Drug Safety Communication: *Clostridium difficile*-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). [Internet]. 2012 Aug 2 [cited 2014 Oct 24]. Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm>
62. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. *Dig Dis Sci*. 2011 Apr;56(4):931–50
63. U.S. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. [Internet]. 2011 Mar 23 [cited 2014 Oct 24]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm>
64. Health Canada. Proton pump inhibitors: risk of bone fractures. [Internet]. 2013 Apr 4 [cited 2014 Oct 24]. Available from: <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php>
65. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. *Gut*. 2014 Apr;63(4):552–8
66. Hess MW, Hoenderop JGJ, Bindels RJM, Drenth JPH. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther*. 2012 Sep;36(5):405–13
67. Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. *PLoS Med*. 2014 Sep;11(9):e1001736
68. U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). [Internet]. 2011 Feb 3 [cited 2014 Oct 24]. Available from: [http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm#Additional Information for healthcare professionals](http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm#Additional%20Information%20for%20healthcare%20professionals)
69. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. *Aliment Pharmacol Ther*. 2007 Aug 15;26(4):545–53
70. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? *Drugs*. 2012 Mar 5;72(4):437–45
71. Loke YK, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. *BMC Med Res Methodol*. 2007;7:32
72. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. *Ther Adv Gastroenterol*. 2012 Jul;5(4):219–32
73. Choosing Wisely®. American Gastroenterological Association. Five Things Physicians and Patients Should Question. [Internet]. 2012 Apr 4 [cited 2014 Oct 24]. Available from: <http://www.choosingwisely.org/doctor-patient-lists/american-gastroenterological-association/>

- 
74. Hastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. *Fam Pract*. 2014 Dec;31(6):625–30
 75. Lødrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. *Scand J Gastroenterol*. 2013 May;48(5):515–22
 76. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. *Am J Gastroenterol*. 2008 Mar;103(3):788–97
 77. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. *Gastroenterology*. 2011 Mar;140(3):1084–91
 78. Education for Quality Improvement in Patient Care. Proton Pump Inhibitor Initiative. EQIP. [Internet]. 2011 Dec [cited 2014 Oct 24]. Available from: <http://web.uvic.ca/~eqip/?q=node/18>
 79. Wolfe M. Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders. [Internet]. 2014 Mar 24 [cited 2014 Oct 24]. Available from: <http://www.uptodate.com/contents/overview-and-comparison-of-the-proton-pump-inhibitors-for-the-treatment-of-acid-related-disorders>